A Ph 1 Study of Epanova® in Healthy Chineses

AstraZeneca14 enrolled

Overview

The purpose of this study is to explore the safety, tolerability, and PK of single and multiple doses of Epanova in healthy male and female Chinese subjects and to allow comparison of these parameters with the Western population studied to date.

This is a single centre, open-label, single- and multiple-dose, PK study in Chinese healthy subjects. Approximately 14 subjects will receive a single oral dose of Epanova 4 g followed by a 72-hour washout period, and then receive Epanova 4 g orally once daily for 14 consecutive days. Subjects will undergo screening evaluations to determine eligibility within 4 weeks (28 days) prior to the first dose of investigational product (IP). Subjects will be admitted to the clinical pharmacology unit approximately 48 hours prior to the first dosing (Day -2) and will stay at the unit until at least 72 hours (Day 20) after their last dose of IP (Day 17). Blood samples will be collected for PK analyses. Subjects will be monitored closely for adverse events throughout the study.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy Subjects

Interventions

EpanovaDRUG

A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects must be willing and able to give written informed consent by signing an IRB-approved Informed Consent Form (ICF) prior to admission to this study and follow the restrictions and procedures outlined for the study. 2. Healthy adult males or females as determined by medical history, physical examination, and laboratory tests. Subjects are to be native Chinese, 18 to 45 years of age (inclusive) at the time of consent. 3. Body mass index (BMI) ≥19 and ≤26 kg/m2 and weigh at least 50 kg. 4. Medically healthy subjects with clinically insignificant screening results (eg, laboratory profiles, medical histories, electrocardiograms \[ECGs\], physical examination). Haemoglobin must be greater than the lower limit of normal. A 12-lead ECG with QTcF \>340 msec and \<450 msec. 5. Acceptable supine blood pressure (BP) and heart rate as determined by the investigator (systolic BP ≤140 mm Hg, and diastolic BP ≤90 mm Hg). 6. For women of childbearing potential (have not had tubal ligation, hysterectomy or surgical procedure for sterilisation), the results from a serum pregnancy test at screening and at Day -2 must be within the normal range. The subject must also agree to use an acceptable method of contraception throughout the trial. Women with an intact uterus are deemed postmenopausal if they are at least age 45, have had cessation of menses for at least 1 year, and have not taken hormones or oral contraceptives (including oestrogen or hormone replacement therapy) during the past 12 months. Key Exclusion Criteria 1. Past history of psychological or physical disorder. 2. An individual who has abnormal laboratory values or an inappropriate current or past medical history for participation based on the PI's decision. 3. Has a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease. 4. Has a positive urine drug/alcohol breath testing at the screening visit or on Day -2. 5. Habitual users of drug(s) of abuse. 6. Has tested positive for human immunodeficiency virus (HIV), hepatitis B (including surface antigen \[HbsAg\] positive healthy carrier), hepatitis C antibodies (HCV), or syphilis. 7. Has used fish oil, other EPA and/or DHA containing supplements within 60 days of admission to the clinic. 8. Has a known sensitivity or allergy to soybeans, fish, and/or shellfish. 9. Has had a history of hypersensitivity or idiosyncratic reaction to compounds related to Epanova. 10. Pregnant or lactating women. 11. Those who have difficulty with blood sampling via a peripheral vein.

Locations (1)

Research Site

Beijing, China